

# Juthathip Mongkolsapaya

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8816587/publications.pdf>

Version: 2024-02-01

72  
papers

15,289  
citations

50170

46  
h-index

79541

73  
g-index

91  
all docs

91  
docs citations

91  
times ranked

20934  
citing authors

#	ARTICLE	IF	CITATIONS
1	Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. <i>Nature Immunology</i> , 2020, 21, 1336-1345.	7.0	1,066
2	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6.	13.5	936
3	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
4	Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. <i>Nature Immunology</i> , 2016, 17, 1102-1108.	7.0	781
5	Cross-Reacting Antibodies Enhance Dengue Virus Infection in Humans. <i>Science</i> , 2010, 328, 745-748.	6.0	780
6	Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. <i>Nature Medicine</i> , 2003, 9, 921-927.	15.2	707
7	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
8	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
9	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021, 184, 2939-2954.e9.	13.5	519
10	Structural basis of potent Zika–dengue virus antibody cross-neutralization. <i>Nature</i> , 2016, 536, 48-53.	13.7	465
11	T Cell Responses to Whole SARS Coronavirus in Humans. <i>Journal of Immunology</i> , 2008, 181, 5490-5500.	0.4	449
12	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	13.5	442
13	MAIT cells are activated during human viral infections. <i>Nature Communications</i> , 2016, 7, 11653.	5.8	428
14	A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. <i>Nature Immunology</i> , 2015, 16, 170-177.	7.0	415
15	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1390-1400.	4.6	336
16	The antigenic anatomy of SARS-CoV-2 receptor binding domain. <i>Cell</i> , 2021, 184, 2183-2200.e22.	13.5	331
17	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. <i>Lancet</i> , The, 2022, 399, 234-236.	6.3	318
18	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. <i>Lancet</i> , The, 2022, 399, 521-529.	6.3	314

#	ARTICLE	IF	CITATIONS
19	Recognition determinants of broadly neutralizing human antibodies against dengue viruses. <i>Nature</i> , 2015, 520, 109-113.	13.7	301
20	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , 2020, 28, 445-454.e6.	5.1	298
21	New insights into the immunopathology and control of dengue virus infection. <i>Nature Reviews Immunology</i> , 2015, 15, 745-759.	10.6	282
22	Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 950-958.	3.6	268
23	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
24	T Cell Responses in Dengue Hemorrhagic Fever: Are Cross-Reactive T Cells Suboptimal?. <i>Journal of Immunology</i> , 2006, 176, 3821-3829.	0.4	244
25	Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. <i>Nature Structural Biology</i> , 1999, 6, 1048-1053.	9.7	235
26	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
27	Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. <i>Wellcome Open Research</i> , 2020, 5, 139.	0.9	179
28	An In-Depth Analysis of Original Antigenic Sin in Dengue Virus Infection. <i>Journal of Virology</i> , 2011, 85, 410-421.	1.5	165
29	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. <i>Nature Medicine</i> , 2022, 28, 1072-1082.	15.2	147
30	Antibodies and tuberculosis. <i>Tuberculosis</i> , 2016, 101, 102-113.	0.8	131
31	The immune response against flaviviruses. <i>Nature Immunology</i> , 2018, 19, 1189-1198.	7.0	126
32	Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas. <i>Journal of Infectious Diseases</i> , 2018, 218, 536-545.	1.9	124
33	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , 2021, 7, 594-602.	5.3	118
34	An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. <i>Nature Immunology</i> , 2022, 23, 50-61.	7.0	110
35	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	13.5	105
36	Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. <i>Nature Immunology</i> , 2017, 18, 1261-1269.	7.0	95

#	ARTICLE	IF	CITATIONS
37	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. <i>Nature Communications</i> , 2021, 12, 6250.	5.8	88
38	Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-Reactivity. <i>Journal of Immunology</i> , 2012, 188, 4971-4979.	0.4	82
39	SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. <i>Wellcome Open Research</i> , 2020, 5, 181.	0.9	81
40	Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. <i>Transfusion Medicine</i> , 2021, 31, 167-175.	0.5	71
41	Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. <i>Nature Communications</i> , 2017, 8, 15411.	5.8	69
42	Rational Zika vaccine design via the modulation of antigen membrane anchors in chimpanzee adenoviral vectors. <i>Nature Communications</i> , 2018, 9, 2441.	5.8	69
43	Sensing of Immature Particles Produced by Dengue Virus Infected Cells Induces an Antiviral Response by Plasmacytoid Dendritic Cells. <i>PLoS Pathogens</i> , 2014, 10, e1004434.	2.1	65
44	Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. <i>Eurosurveillance</i> , 2020, 25, .	3.9	64
45	A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. <i>Nature Immunology</i> , 2019, 20, 1291-1298.	7.0	60
46	Neutrophil Activation and Early Features of NET Formation Are Associated With Dengue Virus Infection in Human. <i>Frontiers in Immunology</i> , 2018, 9, 3007.	2.2	56
47	A haemagglutination test for rapid detection of antibodies to SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 1951.	5.8	54
48	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. <i>Cell Host and Microbe</i> , 2022, 30, 53-68.e12.	5.1	52
49	Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys. <i>Nature Medicine</i> , 2018, 24, 721-723.	15.2	46
50	A Simplified Positive-Sense-RNA Virus Construction Approach That Enhances Analysis Throughput. <i>Journal of Virology</i> , 2013, 87, 12667-12674.	1.5	44
51	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1372-1381.	1.9	41
52	Recent advances in understanding dengue. <i>F1000Research</i> , 2016, 5, 78.	0.8	40
53	The immunopathology of dengue and Zika virus infections. <i>Current Opinion in Immunology</i> , 2017, 48, 1-6.	2.4	38
54	The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses. <i>Cell</i> , 2021, 184, 6052-6066.e18.	13.5	38

#	ARTICLE	IF	CITATIONS
55	Flavivirus maturation leads to the formation of an occupied lipid pocket in the surface glycoproteins. <i>Nature Communications</i> , 2021, 12, 1238.	5.8	37
56	Germline bias dictates cross-serotype reactivity in a common dengue-virus-specific CD8+ T cell response. <i>Nature Immunology</i> , 2017, 18, 1228-1237.	7.0	36
57	Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus. <i>Nature Immunology</i> , 2018, 19, 1248-1256.	7.0	31
58	Antibodies targeting epitopes on the cell-surface form of NS1 protect against Zika virus infection during pregnancy. <i>Nature Communications</i> , 2020, 11, 5278.	5.8	30
59	Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
60	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	2.3	24
61	Autoantibody-dependent amplification of inflammation in SLE. <i>Cell Death and Disease</i> , 2020, 11, 729.	2.7	23
62	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
63	Invariant NKT Cell Response to Dengue Virus Infection in Human. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2955.	1.3	21
64	The immunology of Zika Virus. <i>F1000Research</i> , 2018, 7, 203.	0.8	18
65	Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. <i>Cell Reports</i> , 2019, 26, 1585-1597.e4.	2.9	18
66	Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. <i>Vaccines</i> , 2020, 8, 307.	2.1	18
67	T cell Responses and Dengue Haemorrhagic Fever. <i>Novartis Foundation Symposium</i> , 2008, , 164-176.	1.2	16
68	Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029520.	2.3	16
69	Evolution of neurovirulent Zika virus. <i>Science</i> , 2017, 358, 863-864.	6.0	7
70	SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection. <i>Nature Communications</i> , 2022, 13, .	5.8	6
71	KIR copy number variations in dengue-infected patients from northeastern Thailand. <i>Human Immunology</i> , 2022, 83, 328-334.	1.2	2
72	Omicron BA.1, BA.2 and COVID-19 Booster Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1480-1481.	1.9	2